T

Telix Pharmaceuticals

Develops targeted radiation diagnostics and therapies

Field Service Engineer 1

Full-TimeUpdated on 10/21/2026
No salary listed
Mid
Bachelor's
Canada
In PersonTravel up to 60%, including international, is required.
Field ServiceEquipment Field Service

About the job

Requirements
  • A degree in a relevant engineering discipline or a technical diploma with relevant experience is required.
  • At least 3 years of relevant mechatronic or electrical systems experience is required.
  • Strong verbal and written communication skills in English are required.
  • Familiarity with safe chemical or radiochemical handling for automated radiochemical purification and quality control is required, or willingness to learn it.
  • Experience with installation and commissioning of systems is required.
  • Experience troubleshooting control systems is required.
  • Experience reading and understanding electrical schematics, circuit drawings, and P&ID is required.
  • Experience with inspection tools, power tools, and hand tools is required.
  • Familiarity with power distribution circuits is required.
  • Ability to work with minimum supervision is required.
  • Must be willing to be designated a Nuclear Energy Worker.
  • Must be able to lift up to 50 pounds.
  • Extended hours and shift work may be required, particularly during installation.
  • Travel up to 60%, including international travel, is required.
  • Comply with applicable Quality Management System requirements, procedures, work instructions, and regulatory requirements.
  • Adhere to personal protective equipment requirements and traffic laws while travelling.
  • Complete required safety training and maintain current certifications necessary to perform assigned work.
  • Conduct pre-job hazard assessments and stop work when unsafe conditions or practices are identified.
  • Follow site-specific safety procedures, permit requirements, lockout/tagout processes, and restricted-area controls.
  • Comply with radiation safety requirements, ALARA principles, dosimetry requirements, and local regulatory controls in radiological environments.
  • Use tools, equipment, lifting devices, and material-handling equipment in accordance with training and manufacturer instructions.
  • Report incidents, injuries, near misses, unsafe conditions, and environmental hazards through established company processes.
  • Maintain a fit-for-duty condition, including managing fatigue associated with travel and field service activities.
  • Ensure customer and contractor personnel are not exposed to hazards resulting from work activities under the employee's control.
Responsibilities
  • Lead or participate in installation, preventative maintenance, and technical service projects at customer sites from project initiation through customer acceptance.
  • Install and service equipment by executing qualification procedures and generating installation and service reports.
  • Train customers and ARTMS team members to use and maintain ARTMS equipment, set up automated radiochemical separations, and perform quality control procedures.
  • Maintain tools and tool kits in good working order.
  • Perform site evaluations at potential customer facilities.
  • Provide after-sales virtual and on-site technical support and troubleshooting as needed.
  • Maintain customer and equipment databases, including logging changes and tracking field service activity.
  • Assist with creating and maintaining field service documentation, tool lists, tool sets, and spare-parts lists.
  • Assist with incoming materials inspections as part of quality management.
  • Perform work in accordance with approved installation, maintenance, testing, validation, and commissioning procedures.
  • Maintain accurate, complete, and timely service records, reports, and quality documentation.
  • Identify, document, and escalate deviations, non-conformances, and quality issues through established processes.
  • Support investigation and resolution of customer complaints, field issues, and corrective and preventive actions.
  • Verify work is completed to required specifications and quality standards before release to customers.
  • Maintain data integrity and ensure records are complete, accurate, attributable, and traceable.
  • Participate in continuous improvement initiatives to enhance product quality, reliability, service delivery, and operational efficiency.
  • Support internal and external audits, inspections, and quality assessments as required.
  • Identify and communicate opportunities to improve product design, documentation, training, and service processes based on field experience.
  • Participate in safety meetings, investigations, corrective actions, and continuous improvement initiatives.
Desired Qualifications
  • Knowledge of cyclotron hardware, particularly targetry and target stations.
  • Technical knowledge of radioisotope production, radiochemical separation processes, and radioisotope quality control procedures such as radio-TLC, HPLC, and endotoxin testing.
  • Experience working in radioactive environments.
  • Knowledge and experience working within cGMP and/or ISO 9001 standards.
  • Language abilities in French, Japanese, Mandarin, Cantonese, Portuguese, Korean, German, Swedish, Russian, or another language.

About the company

Telix Pharmaceuticals develops and commercializes diagnostic and therapeutic products that use targeted radiation to diagnose and treat cancer and rare diseases. Its pipeline covers urologic oncology (prostate and kidney cancers), neuro-oncology (glioma), musculoskeletal oncology (sarcoma), and bone marrow conditioning. The treatments work by delivering targeted radiation to diseased tissues, enabling more precise decisions for treatment and allowing for personalized therapy. The company differentiates itself through a global, robust supply chain and a focus on integrating diagnostic and therapeutic options to address unmet medical needs, along with strong commitments to patient care, ethical practices, and environmental responsibility. Telix’s goal is to improve quality of life and outcomes for patients by providing targeted, clinically meaningful diagnostic and therapeutic solutions that support better treatment decisions and personalized care.

Company Size

1,001-5,000

Company Stage

IPO

Headquarters

Melbourne, Australia

Founded

2015

Get referred to Telix Pharmaceuticals

See people who can refer or advise you

Simplify Jobs

Simplify's Take

What believers are saying

  • FDA approved Pixclara on September 13, 2026, opening Telix's first brain-cancer imaging market.
  • H1 2026 revenue reached $477 million, up 22%, with EBITDA rising 146%.
  • BiPASS enrolled 350 patients and Telix aligned with FDA on a U.S. NDA pathway.

What critics are saying

  • Telix still depends on FDA manufacturing acceptance for Zircaix resubmission in 2026.
  • The $2.35 billion ITM deal brings dilution, debt, and integration strain through 2027.
  • Novartis, with Lutathera and Pluvicto, attacks Telix in GEP-NETs and prostate therapy.

What makes Telix Pharmaceuticals unique

  • Telix sells both diagnostics and therapies across the same radiopharmaceutical platform.
  • Illuccix and Gozellix give Telix a commercial prostate imaging franchise in 24 countries.
  • ITM adds isotope manufacturing, distribution, and lutetium-177 supply across more than 65 countries.

Help us improve and share your feedback! Did you find this helpful?

Benefits

  • Annual Performance Bonus
  • Equity-Based Incentive Program
  • Paid Vacation
  • Paid Wellness Days
  • Hybrid Work Options
  • Remote Work Options

Growth & Insights and Company News

Headcount

6 month growth

0%

1 year growth

16%

2 year growth

1%
Yahoo Finance
Oct 19th, 2026
Telix and Ekalia team up to produce astatine-211 in the US for cancer therapy

Telix Pharmaceuticals and Ekalia, a joint venture between IBA and Framatome, will collaborate on US production of astatine-211, an alpha-emitting isotope being studied for targeted alpha therapy. They announced the deal on October 19, 2026. The first IBA alpha-beam cyclotron will be installed at Telix's RLS Radiopharmacies site in Trevose, near Philadelphia. The parties may add more RLS sites as demand grows. The deal gives Telix long-term, priority access to the isotope for its alpha therapy pipeline, including TLX102-Tx, a candidate for glioblastoma and leptomeningeal disease. It will also supply third-party academic and industry programmes. Astatine-211 is promising, but limited production capacity has held back wider use.

Yahoo Finance
Oct 18th, 2026
Three Australian growth stocks with insider backing: PDI Gold, Telix and Codan

Simply Wall St has picked three Australian growth stocks with high insider ownership: PDI Gold, Telix Pharmaceuticals, and Codan. The screen favours fast growers that can handle higher costs as US inflation keeps interest rate risks in focus. PDI Gold (market cap A$4.3 billion) runs the Kiniéro Gold Mine in Guinea. Its reliance on oxide ore could lift costs and squeeze margins once that phase ends. Telix Pharmaceuticals (A$5.3 billion) develops radiopharmaceutical imaging agents and cancer therapies. Its imaging products brought in $803.8 million (USD) in the 2025 financial year, and growth hinges on its late-stage pipeline. Codan (A$11.4 billion) makes radio communications systems and metal detectors. Rising defence spending and demand for unmanned systems are expanding its order book.

Anderson Publishing, Ltd.
Oct 14th, 2026
Telix to present 20 abstracts at EANM 2026 Congress.

Telix to present 20 abstracts at EANM 2026 Congress. October 14, 2026 · News Release Telix has announced that it will be presenting 20 company-related abstracts at the forthcoming 39th Annual Congress of the European Association of Nuclear Medicine (EANM) scheduled for October 17-21, 2026, in Vienna, Austria. Dr. David N. Cade, Chief Medical Officer of Telix, emphasized that the company's robust presence at the event showcases the extensive development of its pipeline, which includes important therapeutic studies, precision diagnostics, and advanced technologies. He noted that the inclusion of 12 abstracts in top-rated oral presentations is a significant acknowledgment of the quality and clinical relevance of Telix's research. A symposium focusing on the future of theranostics in urologic oncology is also planned. Key presentations will feature pivotal trials such as the Phase 3 IPAX BrIGHT trial of TLX101-Tx in recurrent glioblastoma, the Phase 3 LUTEON trial of TLX250-Tx in clear cell renal cell carcinoma (ccRCC), and interim results from the PTherpan-Lu trial of TLX597-Tx in metastatic androgen pathway modulation-resistant prostate cancer (mAPMR). The event will also highlight topline Phase 3 data for TLX591-Px (Illuccix) PET imaging in prostate cancer among Chinese men, as well as real-world applications of TLX250-Px (Zircaix) in ccRCC. Additionally, Telix will sponsor the EANM Sanjiv Sam Gambhir Young Investigator Award to honor the legacy of the esteemed educator. Attendees can visit booth #527 to learn more about collaboration opportunities involving Illuccix(R), the PSMA-PET imaging agent, along with contributions from Telix's theranostic pipeline and innovative medical technologies, including the SENSEI(R) miniature drop-in gamma probe and QDOSE(R) dosimetry software. Sponsored symposium details. Title: The future doesn't wait: The next era of theranostics in urologic oncology. Date & Time: 18-Oct-26, 13:15 - 14:45 Location: Hall F2, Austria Center Vienna Chair: J. Calais, Gustave Roussy, IGR and Université Paris-Saclay, Paris, France * The theranostic revolution * The evolving role of PSMA-PET in prostate cancer * Next-generation PSMA therapeutics: Overcoming today's challenges * Panel discussion * Extending prostate cancer theranostic success to broader GU diseases Selected oral presentations. * ELEGANCE: Prospective pilot study assessing imaging performance of TLX250-Px in patients with hepatocellular carcinoma, biliary tract cancer or gastro-enteropancreatic neuroendocrine neoplasms. * * Date and Time: 18-Oct-26, 08:00 - 09:30 * Presenter: Clement Bailly * HIMIKO: TLX591-Px PET/CT in hepatocellular carcinoma. * * Date and Time: 18-Oct-26, 08:00 - 09:30 * Presenter: Rachel Bardy * Exploring carbonic anhydrase IX as a diagnostic imaging target using TLX250-Px in Von Hippel-Lindau Disease. * * Date and Time: 18-Oct-26, 15:00 - 16:30 * Presenter: Fabrizia Gelardi * LUTEON: Phase 3 study assessing safety and efficacy of TLX250-Tx in advanced ccRCC. * * Date and Time: 18-Oct-26, 15:00 - 16:30 * Presenter: Ghoufrane Tlili * Building the traceability backbone for radiopharmaceutical therapy: First results from the PDIB Secondary Standards Laboratory Network. * * Date and Time: 19-Oct-26, 08:00 - 09:30 * Presenter: Steven Graves With the exception of Illuccix, all products mentioned are investigational and have not received marketing authorization in any jurisdiction. More in theranostics. October 15, 2026 October 6, 2026

Australian Associated Press
Oct 14th, 2026
Telix highlights pivotal trials in prostate, brain and renal cancers and next generation theranostics at EANM.

Telix highlights pivotal trials in prostate, brain and renal cancers and next generation theranostics at EANM. medical research October 14, 2026 MELBOURNE, Australia and INDIANAPOLIS, Oct. 14, 2026 /PRNewswire/ - Telix Pharmaceuticals Limited (ASX: TLX, NASDAQ: TLX, "Telix") today announces that 20 company-related abstracts will be presented at the 39th Annual Congress of the European Association of Nuclear Medicine (EANM) to be held in Vienna, Austria from October 17-21, 2026. Dr. David N. Cade, Telix Group Chief Medical Officer, said, "Our expansive presence at EANM reflects the breadth and maturity of Telix's pipeline, spanning pivotal therapeutic studies, precision diagnostics and next-generation technologies. The selection of 12 abstracts for top-rated oral presentations is a strong recognition of the quality and clinical relevance of this work. We look forward to continuing this discussion at our sponsored symposium on the future of theranostics in urologic oncology." Key presentations include the Phase 3 IPAX BrIGHT trial of TLX101-Tx in recurrent glioblastoma, the Phase 3 LUTEON trial of TLX250-Tx in ccRCC, and interim results from the PTherpan-Lu trial of TLX597-Tx in mAPMR prostate cancer[[1]]. Topline Phase 3 data for TLX591-Px (Illuccix) PET[[2]] imaging of prostate cancer in Chinese men will also be presented, together with real-world experience with TLX250-Px (Zircaix[[3]]) in ccRCC, and research from its targeted alpha therapy and MedTech programs. As in previous years, Telix will support the EANM Sanjiv Sam Gambhir Young Investigator Award, in memory of an extraordinary man and inspiring educator.

Yahoo Finance
Oct 12th, 2026
Three ASX growth stocks with high insider ownership: PDI Gold, Telix and Codan

Simply Wall St has named three Australian growth stocks with high insider ownership, drawn from a screen that surfaced 111 more such companies. Persistent inflation may keep interest rates up, which tends to hurt weakly funded businesses. PDI Gold (ASX:PDI) mines gold in West Africa. Its Kiniéro mine in Guinea brings in about US$156 million in revenue, against US$47 million from Nampala, and the company has a market value of about A$4.4b. Telix Pharmaceuticals (ASX:TLX) makes radiopharmaceutical diagnostics and therapies. Its Precision Medicine unit earns about $705 million and Manufacturing Solutions $277 million, with a market value near A$5.4b. Codan earns A$506 million from communications and A$362 million from metal detection. Its market capitalisation is roughly A$12.1b.